// App-Quantinova.ai

10519 : Phase I expansion cohort to evaluate bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumors.

Researchers

Presenter

  • Sara Michele Federico

Principal Investigators

  • Mary B McCarville

  • Clinton F. Stewart

  • Shenghua Mao

  • Jianrong Wu

  • Andrew M. Davidoff

  • Wayne Lee Furman

  • Victor M. Santana

  • Alberto S. Pappo

  • Fariba Navid

Medical Centers

  • St. Jude Children's Research Hospital, Memphis, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Bevacizumab

  • Sorafenib

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT00665990

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved